Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Invested Capital (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Invested Capital for 10 consecutive years, with $27.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 46.69% year-over-year to $27.8 million, compared with a TTM value of $27.8 million through Dec 2025, down 46.69%, and an annual FY2025 reading of $27.8 million, down 46.69% over the prior year.
  • Invested Capital was $27.8 million for Q4 2025 at VYNE Therapeutics, down from $38.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $127.9 million in Q1 2021 and bottomed at $11.5 million in Q3 2023.
  • Average Invested Capital over 5 years is $55.2 million, with a median of $48.6 million recorded in 2021.
  • The sharpest move saw Invested Capital tumbled 71.29% in 2023, then surged 452.26% in 2024.
  • Year by year, Invested Capital stood at $48.6 million in 2021, then tumbled by 35.85% to $31.2 million in 2022, then skyrocketed by 184.39% to $88.7 million in 2023, then tumbled by 41.3% to $52.1 million in 2024, then plummeted by 46.69% to $27.8 million in 2025.
  • Business Quant data shows Invested Capital for VYNE at $27.8 million in Q4 2025, $38.9 million in Q2 2025, and $44.1 million in Q1 2025.